Autologous Serum Eye Drops in the Management of Limbal Stem Cell Deficiency Associated With Glaucoma Surgery
Issued Date
2023-01-01
Resource Type
ISSN
15422321
eISSN
1542233X
Scopus ID
2-s2.0-85144594751
Pubmed ID
36322388
Journal Title
Eye and Contact Lens
Volume
49
Issue
1
Start Page
19
End Page
24
Rights Holder(s)
SCOPUS
Bibliographic Citation
Eye and Contact Lens Vol.49 No.1 (2023) , 19-24
Suggested Citation
Niruthisard D., Bonnet C., Tanasugarn L., Le B., Deng S.X. Autologous Serum Eye Drops in the Management of Limbal Stem Cell Deficiency Associated With Glaucoma Surgery. Eye and Contact Lens Vol.49 No.1 (2023) , 19-24. 24. doi:10.1097/ICL.0000000000000951 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82731
Title
Autologous Serum Eye Drops in the Management of Limbal Stem Cell Deficiency Associated With Glaucoma Surgery
Author(s)
Other Contributor(s)
Abstract
Purpose:To evaluate safety and efficacy of autologous serum eye drops (AS) in the treatment of limbal stem cell deficiency (LSCD) associated with glaucoma surgery.Methods:Retrospective case series of eyes with glaucoma surgery-induced LSCD treated with AS. Diagnosis of LSCD was confirmed by anterior segment optical coherence tomography, in vivo confocal microscopy, and/or impression cytology. Limbal stem cell deficiency severity was staged using a clinical scoring system (2-10 points). Outcome measures were changes (≥2 points) of the LSCD score and best-corrected visual acuity (BCVA) from the baseline to the last follow-up.Results:Thirteen eyes of 12 consecutive patients treated with 50% AS for at least 3 months were included. The mean age was 78.9±7.5 years and the mean duration of AS use was 20.9±16.8 months. Indications of AS included LSCD progression in eight eyes (61.5%) and visual axis threatening in five eyes (38.5%). The mean LSCD score at baseline (6.7±1.6) was similar to that at last follow-up (6.5±2.2, P=0.625). Two eyes (15.4%) showed improvement, nine eyes (69.2%) were stable, and two eyes (15.4%) worsened. The mean baseline BCVA (0.89±0.64 logMAR) was similar to the mean final BCVA (1.05±0.63 logMAR, P=0.173). There were no serious adverse complications related to AS.Conclusion:AS appears to be well tolerated and may stabilize the progression of LSCD with limited effects. A larger study is necessary to confirm the findings.